기업 프로필 · Healthcare

Danaher Corporation

DHR · 미국
거래소
미국
국가 / 지역
USA
상장일
1979년 1월 5일
직원 수
58,000
웹사이트
www.danaher.com
현재가
$196.5
실시간 · 2026년 7월 27일
베일리 성장 점수
48/100
다소 약함
내재가치 · 3단계 구간 현재가 $196.5 실시간 · 적정 구간과 낙관적 구간 사이

종합 밸류에이션 구간 · 보수적 $115–$140 / 적정 $140–$180 / 낙관적 $205–$230. $196.5 기준, 적정 구간과 낙관적 구간 사이.

보고서 발행 시 $172(2026년 5월 25일)

시가총액US$1346.22억
매출 (TTM)US$251.07억
EBITDAUS$80.28억
순이익률15.95%
ROE7.61%
PER (TTM)34.2
선행 PER22.78
PEG1.27
EPSUS$5.60
배당수익률0.75%
52주 범위US$160.60 – US$241.78
애널리스트 목표주가US$227.61
애널리스트 평가4.6 / 5

데이터 제공: EODHD, 보고 통화 기준 표시. 참고용일 뿐 투자 자문이 아닙니다.

Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. The company operates through Biotechnology, Life Sciences, and Diagnostics segments. The Biotechnology segment provides technologies, consumables, services, and solutions that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, and aseptic fill finish; single-use hardware, consumables, and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services for diagnostic and assay development; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; bioanalytical measurement systems; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; genome sample preparation; microscopes; protein consumables; filtration products; and genomic medicines, such as custom nucleic acid products, and plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, GENEDATA, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX, and SCIEX brands. The Diagnostics segment offers clinical instruments, consumables, software, and services that hospitals, physicians' offices, reference laboratories and other critical care settings use to diagnose disease and make treatment decisions. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was incorporated in 1969 and is headquartered in Washington, the District Of Columbia.

연혁

Danaher Corporation was incorporated in 1969 and was formerly known as Diversified Mortgage Investors, Inc., changing its name to Danaher Corporation in 1984; its IPO date was January 5, 1979. The company was built largely through acquisitions: its Biotechnology segment was founded on Pall and Cytiva, while its Life Sciences segment expanded via deals including AB Sciex, Molecular Devices, Beckman Coulter, Phenomenex, IDT, Aldevron, and Abcam. The company also completed a Veralto spin-off. In February 2026 it announced the acquisition of Masimo for $180 per share in cash, an enterprise value of about $9.9 billion.

업계 내 위치

Danaher is a healthcare company in diagnostics and research, operating through three segments: Biotechnology, Life Sciences, and Diagnostics. In 2025 segment revenue was about $7.293 billion (Biotechnology), $7.334 billion (Life Sciences), and $9.941 billion (Diagnostics), making Diagnostics the largest, with roughly 82% of sales from recurring revenue and about 58,000 employees. Its brands include Cytiva, Pall, Beckman Coulter, Cepheid, Leica, IDT, Abcam, and Radiometer. Named comparable competitors include Thermo Fisher, Agilent, Waters, and Mettler-Toledo; China contributed about $2.631 billion of 2025 revenue, roughly 10.7% of sales.

이 종목에 대한 리포트가 아직 해당 언어로 없습니다.